AttributesValues
Author
Bibliographic Citation
  • Kodjikian Laurent, Souied Eric H., Mimoun Gerard, Mauget-Faysse Martine, Behar-Cohen Francine, Decullier Evelyne, Huot Laure, Aulagner Gilles, Grp GEFAL Study. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2013, 120 (11), pp.2300-2309. ⟨10.1016/j.ophtha.2013.06.020⟩
  • Kodjikian Laurent, Souied Eric H., Mimoun Gerard, Mauget-Faysse Martine, Behar-Cohen Francine, Decullier Evelyne, Huot Laure, Aulagner Gilles. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2013, 120 (11), pp.2300-2309. ⟨10.1016/j.ophtha.2013.06.020⟩
  • Kodjikian Laurent, Souied Eric H., Mimoun Gerard, Mauget-Faysse Martine, Behar-Cohen Francine, Decullier Evelyne, Huot Laure, Aulagner Gilles . Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial . Ophthalmology: Journal of The American Academy of Ophthalmology, 2013, 120 (11), pp.2300-2309 . ⟨10.1016/j.ophtha.2013.06.020⟩
Title
  • Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
dc:date
  • 2013
Digital Object Identifier (DOI)
  • 10.1016/j.ophtha.2013.06.020
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software